Koers Emergent Biosolutions Inc CINNOBER BOAT
Aandelen
0IGA
US29089Q1058
Farmaceutische producten
Omzet 2024 * | 1,02 mld. 940 mln. | Omzet 2025 * | 1,14 mld. 1,05 mld. | Marktkapitalisatie | 324 mln. 300 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -155 mln. -144 mln. | Nettowinst (verlies) 2025 * | -110 mln. -102 mln. | EV/omzet 2024 * | 0,43 x |
Nettoschuld 2024 * | 111 mln. 103 mln. | Nettoschuld 2025 * | 336 mln. 311 mln. | EV/omzet 2025 * | 0,58 x |
K/w-verhouding 2024 * |
-2,07
x | K/w-verhouding 2025 * |
-2,94
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,38% |
Recentste transcriptie over Emergent Biosolutions Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joseph Papa
CEO | Chief Executive Officer | 68 | 21/02 |
Richard Lindahl
DFI | Director of Finance/CFO | 70 | 26-03-18 |
Kelly Warfield
CTO | Chief Tech/Sci/R&D Officer | - | 17-03-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Keith Katkin
BRD | Director/Board Member | 52 | 01-04-22 |
Marvin White
BRD | Director/Board Member | 61 | 01-06-10 |
Louis Sullivan
BRD | Director/Board Member | 90 | 01-01-05 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+45,82% | 765 mld. | |
+40,95% | 632 mld. | |
-6,16% | 354 mld. | |
+19,86% | 331 mld. | |
+9,32% | 299 mld. | |
+18,45% | 248 mld. | |
-0,78% | 219 mld. | |
+11,88% | 216 mld. | |
+5,90% | 164 mld. |